Advances in systemic therapy of small cell cancer of the lung

Expert Review of Anticancer Therapy

Volumn 1, Issue 2, 2001, Pages 211-221

  Daniels, Gregory A ^a   Adjei, Alex A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Gemcitabine; Irinotecan; Paclitaxel; Small cell lung cancer; Topotecan

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; ANTINEOPLASTIC AGENT; CAMPTOTHECIN DERIVATIVE; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DNA TOPOISOMERASE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IDARUBICIN; IFOSFAMIDE; IRINOTECAN; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; MESNA; METHOTREXATE; NAVELBINE; PACLITAXEL; PRINOMASTAT; TAXANE DERIVATIVE; TOPOTECAN; TUMOR ANTIGEN; UNINDEXED DRUG; VINCRISTINE; VINDESINE;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; LUNG SMALL CELL CANCER; REVIEW; SIDE EFFECT;

EID: 0035559068     PISSN: 14737140     EISSN: None     Source Type: Journal    
DOI: 10.1586/14737140.1.2.211     Document Type: Review

References (118)

1. Rising incidence of SCLC in young women
2. Women at double risk of small cell lung cancer
3. Changing patterns of lung cancer histology with age and gender
4. Bone marrow metastases detection in small cell lung cancer. A review
5. Management of small cell cancer of the lung
6. Is there a case for cisplatin in the treatment of small-cell lung cancer? A meta-analysis of a cisplatin-containing regimen versus a regimen without this alkylating agent
7. Randomized study of CODE versus alternating CAV/EP for extensive-stage small-cell lung cancer: An Intergroup Study of the National Cancer Institute of Canada Clinical Trials Group and the Southwest Oncology Group
8. Randomized study of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer: A Phase III trial of the Southeastern Cancer Study Group
9. Randomized trial of cyclophosphamide, doxorubicin and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer
10. Current guidelines for the management of small cell lung cancer
11. The role of carboplatin in the treatment of small-cell lung cancer
12. Randomized comparison of etoposidecisplatin versus etoposide-carboplatin and irradiation in small cell lung cancer: A Hellenic Cooperative Oncology Group study
13. The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma: A randomized study of 457 patients: 'Petites Cellules' Group
14. Pilot study with weekly chemotherapy for patiennts with extensive small cell lung cancer: An Eastern Cooperative Oncology Group Study (PA586)
15. A Phase II study of combined chemoradiotherapy for limited disease-small-cell lung cancer
16. Standard versus alternating non-cross-resistant chemotherapy in extensive small cell lung cancer: An EORTC Phase III trial
17. Standard combination versus alternating chemotherapy in small cell lung cancer: A randomised clinical trial including 394 patients
18. Dose-intensive weekly alternating chemotherapy for patients with small cell lung cancer: Randomized trial, can it improve survival of patients with good prognostic factors
19. Effects of granulocyte-macrophage colony-stimulating factor of V-ICE chemotherapy in small-cell lung cancer: A perspective randomized study of 300 patients
20. High-dose chemotherapy: Is it standard management for any common solid tumor?
21. Standard- and high-dose etoposide, ifosfamide, carboplatin and epirubicin in 100 patients with small-cell lung cancer: A mature follow-up report
22. Dose-intensity of a four-drug chemotherapy regimen with or without recombinant human granulocyte-macrophage colony-stimulating factor in extensive-stage small-cell lung cancer: A multicenter randomizrd Phase III study
23. Lenograstim as support for ACE chemotherapy of small-cell lung cancer: A Phase III, multicenter, randomized study
24. Phase III study of intensive weekly chemotherapy with recombinant human granulocyte colony-stimulating factor versus standard chemotherapy in extensive-disease small-cell lung cancer
25. A Phase I dose escalation study of multicyclic, dose-intensive chemotherapy with peripheral blood stem cell support for small cell lung cancer
26. High-dose combined alkylating agent therapy with autologous stem cell support and chest radiotherapy for limited small-cell lung cancer
27. Hematopoietic stem cell transplantation for small cell lung cancer
28. Dose-intensive therapy for limited-stage small-cell lung cancer: Long-term outcome
29. Oral etoposide and palliative treatment for small-cell lung cancer
30. Single-agent oral etoposide for elderly small cell lung cancer patients
31. Cyclophosphamide and etoposide for non-small cell and small cell lung cancer
32. Combination chemotherapy with low doses of weekly carboplatin and oral etoposide in poor risk small cell lung cancer
33. Phase II trial of carboplatin plus oral etoposide for elderly patients with small-cell lung cancer
34. Oral chemotherapy for poor risk small-cell lung cancer patients with combined idarubicin and etoposide
35. Five-day oral etoposide treatment for advanced small-cell lung cancer: Randomized comparison with intravenous chemotherapy
36. Comparison of oral etoposide and standard intravenous multidrug chemotherapy for small-cell lung cancer: A stopped multicenter randomised trial
37. Twenty years of Phase III trials for patients with extensive-stage small-cell cancer: Perceptible progress
38. Second-line chemotherapy and its evaluation in small cell lung cancer
39. New chemotherapy agents for small cell lung cancer
40. Taxanes: An overview of the pharmacokinetics and pharmacodynamics
41. Taxol: A novel radiation sensitizer
42. Phase II study of paclitaxel in patients with extensive-disease small-cell lung cancer: An Eastern Cooperative Oncology Group study
43. Paclitaxel and G-CSF in previously untreated patients with extensive stage small-cell lung cancer: A Phase II study of the North Central Cancer Treatment Group
44. Concurrent paditaxel-containing regimens and thoracic radiation therapy for limited-disease small cell lung cancer
45. Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: Update and preliminary survival analysis
46. Phase II study of doxorubicin and paclitaxel as second-line chemotherapy of small-cell lung cancer: A hoosier oncology group trial
47. Paclitaxel, carboplatin and oral etoposide: A Phase II trial in limited-stage small cell lung cancer
48. A Phase II study evaluating the efficacy of carboplatin, etoposide and paclitaxel with granulocyte colony-stimulating factor in patients with stage IIIB and IV non-small cell lung cancer and extensive small cell lung cancer
49. Paclitaxel, carboplatin and extended-schedule oral etoposide for small-cell lung cancer
50. Cisplatin, etoposide and paclitaxel in the treatment of patients with extensive small-cell lung carcinoma
51. A Phase I study of cisplatin, etoposide and paclitaxel in small cell lung cancer
52. Multi-institutional Phase I/II trial of paclitaxel, cisplatin and etoposide with concurrent radiation for limited-stage small-cell lung carcinoma
53. A randomized study of etoposide and carboplatin with or without paclitaxel in the treatment of small cell lung cancer
54. A Phase I study of paclitaxel, etoposide and cisplatin in extensive stage small cell lung cancer
55. Paclitaxel and carboplatin in the treatment of small-cell lung cancer patients resistant to cyclophosphamide, doxorubicin and etoposide: A non-cross-resistant schedule
56. Phase II study of docetaxel (taxotere) in patients with previously untreated extensice small cell lung cancer
57. Combination chemotherapy with tamoxifen, ifosfamide, epirubicin and cisplatin in extensive-disease small-cell lung cancer
58. Activity of docetaxel (Taxotere) in small cell lung cancer
59. Evaluation of docetaxel in previously untreated extensive-stage small cell lung cancer: A Southwest Oncology Group Phase II trial
60. A Phase II trial of intravenous vinorelbine in previously untreated patients with extensive small cell lung cancer, Southwest Oncology Group study
61. Phase II study of vinorelbine in heavily previously treated small cell lung cancer
62. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients. EORTC Lung Cancer
63. Eukaryotic DNA topoisomerase I: Genome gatekeeper and its intruders, camptothecins
64. Topotecan versus cyclophosphamide, doxorubicin and vincristine for the treatment of recurrent small-cell lung cancer
65. Topotecan: A review of its efficacy in small cell lung cancer
66. Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: A Phase II study in patients with refractory and sensitive disease
67. Conversion of irinotecan (CPT-11) to its active metabolite, 7-ethyl-10-hydorxycamptothecin (SN-38), by human liver carboxylesterase
68. Second-line chemotherapy with weekly cisplatin and irinotecan in patients with refractory lung cancer
69. Synergism between cisplatin and topoisomerase I inhibitors, NB-506 and SN-38, in human small cell lung cancer cells
70. Effect of CPT-11 in combination with other anticancer agents in lung cancer cells
71. Combination of cisplatin, ifosfamide and irinotecan with rhG-CSF support for the tratment of refractory or relapsed small-cell lung cancer
72. A randomized Phase III study of irinotecan and cisplatin versus etoposide and cisplatin in extensive disease small cell lung cancer
73. Evaluation of new drugs in small cell lung cancer: The activity of gemcitabine
74. Gemcitabine is an active new agent in previously untreated extensive small cell lung cancer (SCLC)
75. In vitro cross-resistance and collateral sensitivity in seven resistant small-cell lung cancer cell lines: Preclinical identification of suitable drug partners to taxotere, taxol, topotecan and gemcitabine
76. Synergistic effect of gemcitabine and irinotecan (CPT-11) on breast and small cell lung cancer cell lines
77. A Phase I study of gemcitabine/cisplatin/etoposide in the treatment of small-cell lung cancer
78. Gemcitabine and etoposide in small cell lung cancer: Phase I and II trials
79. New therapeutic strategies for lung cancer: Biology and molecular biology come of age
80. Phase I and imaging trial of a monoclonal antibody directed against gastrin-releasing peptide in patients with lung cancer
81. [Arg6,D-Trp7,9,NmePhe8]-substance P (6-11) activates JNK and induces apoptosis in small cell lung cancer cells via an oxidant-dependent mechanism
82. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer
83. Long term survival of patients with small cell lung cancer agter adjuvant treatment with the anti-idiotypic antibody BEC2 plus Bacillus Calmetter-Guerin
84. Adjunctive interferon-α-2c in stage IIIB/IV small-cell lung cancer: A Phase III trial
85. Interferon-α and 13-cis-retinoic acid as maintenance therapy after high-dose combination chemotherapy with growth factor support for small cell lung cancer: A feasibility study
86. Concomitant chemotherapy and IFN-α for small cell lung cancer: A randomized multicenter Phase III study
87. A Phase II study of all-trans-retinoic acid plus cisplatin and etoposide in patients with extensive stage small cell lung carcinoma: An Eastern Cooperative Oncology Group Study
88. Expression and prognostic significance of metalloproteinases and their tissue inhibitors in patients with small-cell lung cancer
89. Phase I clinical and pharmacokinetics study of bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma
90. Decreased levels of the cell-cycle inhibitors p27Kip1 protein: Prognostic implication in primary breast cancer
91. Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic strategies
92. Mdm2 promotes the rapid degradation of p53
93. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas
94. Cullin-3 targets cyclin E for ubiquitination and controls S phase in mammalian cells
95. 1 phosphorylation on threonine-286 prevents its rapid degradation via the ubiquitin-proteasome pathway
96. Molecular structure of a major insulin/mitogen-activated 70 kDa S6 protein kinase
97. PDGR-and insulin-dependent pp70S6k activation mediated by phosphatidylinositol-3-OH kinase
98. Rapamycin inhibits constitutive p7026k phosphorylation, cell proliferation and colony formation in small cell lung cancer cells
99. Translational controls impinging on the 5′-untranslated region and initiation factor proteins
100. PHAS/4E-BPs as regulators of mRNA translation and cell proliferation
101. RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1
102. The mRNA 5′ cap-binding protein eIF4E and control of cell growth
103. Blocking oncogenic ras signaling for cancer therapy
104. Immunohistochemical detection of mutant p53 protein in small-cell lung cancer: Relationship to treatment outcome
105. Expression of DNA topoisomerase II α and topoisomerase II β genes predicts survival and response to chemotherapy in patients with small cell lung cancer
106. Myc family DNA amplification in tumors and tumor cell lines from patients with small-cell lung cancer
107. Expression of epidermal growth factor receptors in four histologic cell types of lung cancer
108. Expression of the epidermal growth factor receptor in human small cell lung cancer cell lines
109. Survival in small cell lung carcinoma is independent of Bcl-2 expression
110. Expression of bcl-2-protein in small cell lung cancer
111. Is small cell lung cancer the perfect target for anti-telomerase treatment?
112. The human p19ARF protein encoded by the beta transcript of the p16INK4a gene is frequently lost in small cell lung cancer
113. High resolution chromosome 3p allelotyping of human lung cancer and preneoplastic/preinvasive bronchial epithelium reveals multiple, discontinuous sites of 3p allele loss and three regions of frequent breakpoints
114. Effects of recombinant neutral endopeptidase (EC 3.4.24.11) on the growth of lung cancer cell lines in vitro and in vivo
115. Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: A Phase I study
116. Teniposide (VM-26) as a single drug treatment for patients with extensive small cell lung carcinoma: A Phase II study of the Southwest Oncology Group
117. Phase II study of topotecan in patients with extensive-stage small-cell carcinoma of the lung: An Eastern Cooperative Oncology Group Trial
118. A Phase II trial of intravenous vinorelbine in previously untreated patient with extensive small cell lung cancer, Southwest Oncology Group study